HTT

HTT Molekülinformation

Englischer Name	Huntingtin	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	10	Target-Alias	Huntingtin，HD protein，HD，HTT，Huntington Disease Protein，IT15，Huntingtin (Huntington Disease)，LOMARS，Huntingtin Protein
Höchste Forschungs- und Entwicklungsphase	Phase 3 Clinical

Englischer Name	Huntingtin
Target-Alias	Huntingtin，HD protein，HD，HTT，Huntington Disease Protein，IT15，Huntingtin (Huntington Disease)，LOMARS，Huntingtin Protein
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	10
Höchste Forschungs- und Entwicklungsphase	Phase 3 Clinical

HTT Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag & MBP Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
HTT-H51M5	Human	E. coli	Human HTT Protein, MBP,His Tag (MALS verified)				In den Warenkorb legen

Gesamtmenge1

HTT Molekülhintergrund

Huntingtin is the protein coded for by the HTT gene. Autosomal dominant mutation in the Huntingtin (Htt) protein is the cause of Huntington’s Disease (HD). In HD, the polyglutamine (polyQ) domain in the N-terminal sequenceof the protein is expanded beyond a threshold of 36 glutamines. mutant polyQ expansion strongly correlates in an inverse manner to disease age of onset.

HTT Molekülalias

HTT,Htt,Huntingtin

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Tominersen	RG-6042; RO-7234292; ISIS-443139	Phase 3 Clinical	Ionis Pharmaceuticals Inc	Huntington Disease	Details
SKY-0515	SKY-0515	Phase 3 Clinical	Skyhawk Therapeutics Inc	Huntington Disease; Nervous System Diseases	Details
Votoplam	PTC-518; PTC518	Phase 3 Clinical	Ptc Therapeutics Inc	Huntington Disease	Details
WVE-003	WVE-003	Phase 2 Clinical	Wave Life Sciences Ltd	Huntington Disease	Details
NA-841	NA-841; NA841	Phase 2 Clinical	Biomed Industries Inc	Huntington Disease	Details
SPK-10001	SPK-10001; RG-6662; HTT miRNA GT	Phase 2 Clinical	Spark Therapeutics Inc	Huntington Disease	Details
ER-2001	ER-2001; ER2001	Phase 2 Clinical	Shenzhen Aima Biotechnology Co Ltd	Huntington Disease	Details
ARO-HTT	ARO-HTT; SRP-1005	Phase 1 Clinical	Arrowhead Pharmaceuticals Inc	Huntington Disease	Details
ALN-HTT-02	ALN-HTT-02; ALN-HTT02	Phase 1 Clinical	Alnylam Pharmaceuticals Inc	Huntington Disease	Details
PTC-607	PTC-607	Phase 1 Clinical	Ptc Therapeutics Inc	Huntington Disease	Details